Diane D Liu Selected Research

Adenocarcinoma of Lung

7/2013	ETS2 mediated tumor suppressive function and MET oncogene inhibition in human non-small cell lung cancer.
1/2013	Fibulin-2 is a driver of malignant progression in lung adenocarcinoma.
4/2011	Abnormalities of the TITF-1 lineage-specific oncogene in NSCLC: implications in lung cancer pathogenesis and prognosis.
1/2011	miR-200 Inhibits lung adenocarcinoma cell invasion and metastasis by targeting Flt1/VEGFR1.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Diane D Liu Research Topics

Disease

52	Neoplasms (Cancer) 01/2023 - 05/2002
17	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2021 - 05/2002
15	Breast Neoplasms (Breast Cancer) 10/2023 - 10/2011
10	Lung Neoplasms (Lung Cancer) 12/2019 - 01/2003
9	Neoplasm Metastasis (Metastasis) 01/2024 - 05/2003
7	Pain (Aches) 11/2021 - 01/2018
6	Carcinogenesis 04/2014 - 01/2002
5	Squamous Cell Carcinoma (Epidermoid Carcinoma) 04/2011 - 12/2005
4	Fatigue 12/2021 - 01/2016
4	Glioblastoma (Glioblastoma Multiforme) 01/2021 - 04/2009
4	Adenocarcinoma of Lung 07/2013 - 01/2011
4	Carcinoma (Carcinomatosis) 05/2011 - 07/2002
3	Pathologic Complete Response 01/2020 - 10/2011
3	Adenocarcinoma 04/2011 - 04/2009
2	Triple Negative Breast Neoplasms 01/2024 - 01/2023
2	Cancer Pain 01/2021 - 01/2020
2	Dyspnea (Shortness of Breath) 01/2019 - 01/2016
2	Infections 02/2018 - 07/2002
2	Agranulocytosis (Granulocytopenia) 02/2018 - 07/2002
2	Nausea 01/2018 - 12/2015
2	Glioma (Gliomas) 01/2014 - 04/2009
2	Brain Neoplasms (Brain Tumor) 01/2014 - 05/2009
2	Metaplasia 02/2010 - 02/2003
2	Squamous Cell Carcinoma of Head and Neck 06/2007 - 12/2005
1	Noninfiltrating Intraductal Carcinoma (DCIS) 01/2023
1	Long Term Adverse Effects 12/2021
1	Chronic Disease (Chronic Diseases) 11/2021
1	Obesity 01/2021
1	Sarcopenia 01/2021
1	Hereditary Nonpolyposis Colorectal Neoplasms (Hereditary Nonpolyposis Colorectal Cancer) 01/2021
1	Breast Carcinoma In Situ 01/2020
1	Ependymoma 01/2020
1	Hyperplasia 01/2020
1	Medulloblastoma 01/2020
1	Circulating Neoplastic Cells 01/2020
1	Poisoning 01/2020
1	Inflammatory Breast Neoplasms 01/2020

Drug/Important Bio-Agent (IBA)

9	Opioid Analgesics (Opioids)IBA 01/2021 - 12/2017
8	Proteins (Proteins, Gene)FDA Link 04/2014 - 03/2005
6	Estrogen ReceptorsIBA 10/2023 - 08/2007
6	ErbB Receptors (EGF Receptor)IBA 01/2016 - 04/2005
4	Biomarkers (Surrogate Marker)IBA 10/2023 - 12/2002
3	Messenger RNA (mRNA)IBA 01/2023 - 09/2002
3	Trastuzumab (Herceptin)FDA Link 01/2020 - 01/2016
3	Docetaxel (Taxotere)FDA Link 02/2018 - 04/2009
3	Erlotinib Hydrochloride (CP 358,774)FDA Link 02/2018 - 04/2005
3	Bevacizumab (Avastin)FDA Link 01/2016 - 04/2005
3	Carboplatin (JM8)FDA LinkGeneric 06/2015 - 04/2009
3	Tyrosine Kinase InhibitorsIBA 06/2015 - 04/2005
3	Paclitaxel (Taxol)FDA LinkGeneric 06/2015 - 11/2003
3	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 09/2014 - 04/2005
3	RetinoidsIBA 07/2005 - 02/2003
2	Phosphotransferases (Kinase)IBA 01/2024 - 01/2023
2	Protons (Proton)IBA 01/2021 - 01/2021
2	Celecoxib (Celebrex)FDA Link 01/2020 - 02/2010
2	Cisplatin (Platino)FDA LinkGeneric 02/2018 - 11/2003
2	Morphine (MS Contin)FDA LinkGeneric 01/2018 - 12/2017
2	4-amino-4'-hydroxylaminodiphenylsulfone (HADS)IBA 01/2018 - 01/2016
2	Indicators and Reagents (Reagents)IBA 01/2016 - 01/2003
2	Monoclonal AntibodiesIBA 03/2015 - 04/2005
2	Transcription Factors (Transcription Factor)IBA 07/2013 - 08/2008
2	Progesterone Receptors (Progesterone Receptor)IBA 02/2012 - 08/2007
2	Cadherins (E-Cadherin)IBA 05/2009 - 03/2005
2	alpha-Tocopherol FDA Link 01/2009 - 03/2005
2	Cyclin D1IBA 01/2009 - 02/2003
2	Insulin-Like PeptidesIBA 07/2006 - 07/2005
2	retinoic acid receptor betaIBA 02/2003 - 01/2003
1	src-Family KinasesIBA 10/2023
1	Aromatase InhibitorsIBA 10/2023
1	Dasatinib (BMS 354825)FDA Link 10/2023
1	Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA 01/2023
1	AntigensIBA 01/2023
1	Protein Subunit VaccinesIBA 01/2023
1	Bexarotene (LGD1069)FDA Link 01/2023
1	HLA Antigens (Human Leukocyte Antigens)IBA 01/2023
1	HER2 peptide (369-377)IBA 01/2023
1	Dexamethasone (Maxidex)FDA LinkGeneric 12/2021
1	talimogene laherparepvecIBA 11/2021
1	GlutaminaseIBA 01/2021
1	Naproxen (Naprosyn)FDA LinkGeneric 01/2021
1	Radium-223IBA 01/2020
1	Epithelial Cell Adhesion MoleculeIBA 01/2020
1	Hormones (Hormone)IBA 01/2020
1	Hypnotics and Sedatives (Sedatives)IBA 12/2019
1	BenzodiazepinesIBA 12/2019

Therapy/Procedure

20	Therapeutics 10/2023 - 02/2003
12	Palliative Care (Palliative Therapy) 11/2021 - 01/2017
10	Chemoprevention 10/2023 - 01/2002
7	Drug Therapy (Chemotherapy) 01/2021 - 05/2010
7	Radiotherapy 01/2021 - 12/2005
6	Neoadjuvant Therapy 01/2020 - 10/2011
2	Physical Therapy Modalities (Physical Therapy Technique) 12/2021 - 01/2021
2	Immunotherapy 11/2021 - 01/2011
2	Intensity-Modulated Radiotherapy (Radiotherapy, Intensity Modulated) 01/2021 - 01/2021
2	Perioperative Period 02/2018 - 03/2014
1	Continuity of Patient Care 10/2021
1	Patient Transfer (Patient Dumping) 10/2021
1	Preoperative Exercise 01/2021
1	Intraventricular Infusions 01/2020
1	Precision Medicine 12/2019